KPC Pharmaceuticals Inc (600422):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】KPC Pharmaceuticals Inc (600422) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8105)・商品コード:DATA904C8105
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:30
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
KPC Pharmaceuticals Inc (KPC), formerly Kunming Pharmaceutical Corp, a subsidiary of Holley Group Co Ltd, is a manufacturer of botanical drugs and other pharmaceutical products. The company offers panax notoginseng, gastrodine, artemether and special botanical drugs. It also offers drugs such as xuesaitong Injection, xuesaitong soft capsules, xuesaitong freeze-dried powder for injection, gastrodin capsules, acetagastrodin tablets, gastrodin tablets, colchicines tablet, fibrauretine tablets and injection, and breviscapine tablets, among others. KPC conducts research and development to develop new drugs. The company’s drugs are used for central nervous system disorder, cardiovascular disorders and malaria. It offers its products under the brands Luotai, Tianxuanqing, Artemedine, Artem and Arco. KPC is headquartered in Kunming, China.

KPC Pharmaceuticals Inc (600422) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
KPC Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Rani Therapeutics Raises Funds in Financing 12
Partnerships 14
KPC Pharma to Form Joint Venture 14
Kunming Pharma Forms Joint Venture With Uzfarmprom State Joint Stock Company 15
Equity Offering 16
KPC Pharma Receives Approval for Private Placement of Shares 16
Kunming Pharma Plans to Raise USD203 Million in Private Placement Of Shares 17
Debt Offering 18
KPC Pharma to Raise USD48 Million in Public Offering of Bonds 18
Kunming Pharma Plans to Raise USD49 Million in Public Offering of Bonds 19
Acquisition 20
KPC Pharma Plans to Acquire 60% Stake in Dali Based Pharma Company for USD2.7 Million 20
KPC Pharma to Acquire 60% Stake in Yun’nan-Based Pharma Company for USD3 Million 21
KPC Pharma to Acquire 70% Stake in Zhejiang Holley Nanhu Pharma from Beijing Holley-Cotec Pharma for USD4 Million 22
KPC Pharma Acquires 70% Stake in Beijing Hua Fang Ketai Pharma for USD39 Million 23
KPC Pharma Plans to Acquire Chongqing based Pharma Company from Beijing based Medical Company for USD8 Million 24
KPC Pharma Plans to Acquire Beijing based Pharma Company for USD1.4 Million 25
KPC Pharma Acquires 49% Stake in Kunming-based Pharma Company from Kunming Baker Norton Pharma for USD48 Million 26
KPC Pharma to Acquire Stake in Rani Therapeutics for USD5 Million 27
KPC Pharmaceuticals Inc – Key Competitors 28
KPC Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
KPC Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
KPC Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Rani Therapeutics Raises Funds in Financing 12
KPC Pharma to Form Joint Venture 14
Kunming Pharma Forms Joint Venture With Uzfarmprom State Joint Stock Company 15
KPC Pharma Receives Approval for Private Placement of Shares 16
Kunming Pharma Plans to Raise USD203 Million in Private Placement Of Shares 17
KPC Pharma to Raise USD48 Million in Public Offering of Bonds 18
Kunming Pharma Plans to Raise USD49 Million in Public Offering of Bonds 19
KPC Pharma Plans to Acquire 60% Stake in Dali Based Pharma Company for USD2.7 Million 20
KPC Pharma to Acquire 60% Stake in Yun'nan-Based Pharma Company for USD3 Million 21
KPC Pharma to Acquire 70% Stake in Zhejiang Holley Nanhu Pharma from Beijing Holley-Cotec Pharma for USD4 Million 22
KPC Pharma Acquires 70% Stake in Beijing Hua Fang Ketai Pharma for USD39 Million 23
KPC Pharma Plans to Acquire Chongqing based Pharma Company from Beijing based Medical Company for USD8 Million 24
KPC Pharma Plans to Acquire Beijing based Pharma Company for USD1.4 Million 25
KPC Pharma Acquires 49% Stake in Kunming-based Pharma Company from Kunming Baker Norton Pharma for USD48 Million 26
KPC Pharma to Acquire Stake in Rani Therapeutics for USD5 Million 27
KPC Pharmaceuticals Inc, Key Competitors 28
KPC Pharmaceuticals Inc, Subsidiaries 29

List of Figures
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
KPC Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
KPC Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

★調査レポート[KPC Pharmaceuticals Inc (600422):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8105)販売に関する免責事項を必ずご確認ください。
★調査レポート[KPC Pharmaceuticals Inc (600422):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆